Condition
Lamellar Ichthyosis
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 3 (1)
Trial Status
Completed2
Unknown1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03738800Phase 2TerminatedPrimary
A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis
NCT03041038Phase 2Completed
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
NCT01222000Phase 3UnknownPrimary
Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous
NCT00001292Completed
Study of Scaling Disorders and Other Inherited Skin Diseases
Showing all 4 trials